The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.
本发明提供了一类新型的化合物,其
化学式为I:(I),以及包含这些化合物的药物组合物,用于治疗或预防与异常或失调的激酶活性相关的疾病或障碍,尤其是涉及异常激活c-kit、PDGFRα和PDGFRβ激酶的疾病或障碍。